PRG2

Summary

PRG2 (proteoglycan 2, pro eosinophil major basic protein, HGNC:9362) is a protein-coding gene on chromosome 11q12.1, encoding Bone marrow proteoglycan (P13727). Cytotoxin and helminthotoxin.

The protein encoded by this gene is the predominant constituent of the crystalline core of the eosinophil granule. High levels of the proform of this protein are also present in placenta and pregnancy serum, where it exists as a complex with several other proteins including pregnancy-associated plasma protein A (PAPPA), angiotensinogen (AGT), and C3dg. This protein may be involved in antiparasitic defense mechanisms as a cytotoxin and helminthotoxin, and in immune hypersensitivity reactions. The encoded protein contains a peptide that displays potent antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and fungi. It is directly implicated in epithelial cell damage, exfoliation, and bronchospasm in allergic diseases. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 5553 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 93 total — 2 pathogenic
• MANE Select transcript: NM_002728

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9362
Approved symbol	PRG2
Name	proteoglycan 2, pro eosinophil major basic protein
Location	11q12.1
Locus type	gene with protein product
Status	Approved
Aliases	MBP, BMPG, proMBP
Ensembl gene	ENSG00000186652
Ensembl biotype	protein_coding
OMIM	605601
Entrez	5553

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 retained_intron

ENST00000311862, ENST00000525955, ENST00000530105, ENST00000533605, ENST00000886024, ENST00000886025

RefSeq mRNA: 4 — MANE Select: NM_002728 NM_001243245, NM_001302926, NM_001302927, NM_002728

CCDS: CCDS58133, CCDS7955

Canonical transcript exons

ENST00000311862 — 6 exons

Exon	Start	End
ENSE00001309153	57386780	57387533
ENSE00002185412	57390596	57390650
ENSE00003521336	57389010	57389317
ENSE00003550821	57388577	57388708
ENSE00003565146	57389887	57389956
ENSE00003655795	57387754	57387865

Expression profiles

Bgee: expression breadth ubiquitous, 120 present calls, max score 99.86.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 30.7949 / max 19422.1042, expressed in 162 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119746	30.3963	156
119747	0.3078	37
119745	0.0908	12

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
placenta	UBERON:0001987	99.86	gold quality
bone marrow	UBERON:0002371	91.07	gold quality
bone marrow cell	CL:0002092	84.59	gold quality
right lobe of liver	UBERON:0001114	76.17	gold quality
skin of leg	UBERON:0001511	73.45	gold quality
subcutaneous adipose tissue	UBERON:0002190	72.47	gold quality
zone of skin	UBERON:0000014	70.99	gold quality
spleen	UBERON:0002106	68.12	gold quality
skin of abdomen	UBERON:0001416	68.07	gold quality
adipose tissue	UBERON:0001013	66.74	gold quality
liver	UBERON:0002107	66.49	gold quality
monocyte	CL:0000576	65.00	gold quality
blood	UBERON:0000178	64.81	gold quality
thoracic mammary gland	UBERON:0005200	63.83	gold quality
leukocyte	CL:0000738	63.76	gold quality
lower esophagus mucosa	UBERON:0035834	61.23	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	61.13	gold quality
granulocyte	CL:0000094	60.94	gold quality
omental fat pad	UBERON:0010414	60.41	gold quality
right lung	UBERON:0002167	60.17	gold quality
smooth muscle tissue	UBERON:0001135	58.83	gold quality
esophagus mucosa	UBERON:0002469	58.28	gold quality
upper lobe of left lung	UBERON:0008952	58.18	gold quality
mucosa of stomach	UBERON:0001199	58.00	gold quality
left lobe of thyroid gland	UBERON:0001120	57.90	gold quality
left uterine tube	UBERON:0001303	57.24	gold quality
thyroid gland	UBERON:0002046	56.67	gold quality
saliva-secreting gland	UBERON:0001044	56.50	gold quality
minor salivary gland	UBERON:0001830	56.37	gold quality
tibial nerve	UBERON:0001323	55.98	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	113530.82
E-MTAB-6701	yes	87412.14
E-HCAD-23	yes	54444.03
E-MTAB-6678	yes	44424.19
E-MTAB-10042	yes	16420.81
E-MTAB-9067	yes	11883.78
E-CURD-112	yes	9341.56
E-MTAB-10432	yes	5546.29
E-MTAB-7407	yes	3063.42
E-HCAD-6	yes	2095.85
E-HCAD-4	yes	1343.13
E-CURD-77	yes	1011.53
E-MTAB-8142	yes	14.40
E-HCAD-10	yes	12.19
E-ANND-3	no	2.76

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPB, CEBPE, GATA1, GATA2, GFI1, SPI1

miRNA regulators (miRDB)

54 targeting PRG2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-3140-5P	99.39	69.04	1136
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-3678-3P	99.31	67.10	1432

Literature-anchored findings (GeneRIF, showing 30)

• Transcription is regulated by novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms. (PMID:12202480)
• IGF bioactivity is regulated by reversible cell surface binding of PAPP-A, which in turn is regulated by proMBP (PMID:12370176)
• MBP’s structure is described, and its ability to bind to pregnancy-associated plasma protein A explained (PMID:12421832)
• Deposits of eosinophilic MBP are found on the surface of eosinophils and damaged muscle fibers surrounded by eosinophils in patients with idiopathic eosinophilic myositis. (PMID:12534990)
• MBP stimulates a Src kinase-dependent activation of class I(A) phosphoinositide 3-kinase and, in turn, activation of protein kinase C zeta in neutrophils, which contributes to the activation of NADPH oxidase and resultant superoxide production. (PMID:14500673)
• Proform of MPB forms a covalent complex with PAPPA in which PAPPA is inhibited. (PMID:14988014)
• the proform of eosinophil major basic protein inhibits the proteolytic activity of PAPP-A (PMID:15647258)
• two regions shown previously to contain the cytotoxic and cytostimulatory properties of MBP are accessible for ligand interaction in cell surface-bound MBP (PMID:16940047)
• Compared to MBP1, which is present in eosinophils, basophils, and a human mast cell line, homologous MBP2 is present only in eosinophils and may be a useful biomarker for eosinophil-associated diseases. (PMID:17082653)
• Pregnancy-associated plasma protein A is involved in processes preceding vulnerable plaque development in acute coronary syndrome. (PMID:17223728)
• MBP and NE collaborated to cause the pathological effects of nasal polyps. (PMID:18476621)
• The expression of MBP in nasal mucus obtained from chronic rhinosinusitispatients was obviously higher than that of nasal mucus obtained from controls. (PMID:18720885)
• knockdown of endogenous MBP-1 is involved in cellular senescence of HFF through p53-p21 pathway. (PMID:18852884)
• No variation in genes major basic protein for Atopic dermatitis pathogenesis in this German cohort (PMID:19014520)
• The significantly elevated levels of proMBP in myelofibrosis patients implies that proMBP could be an important stromal cytokine in bone marrow fibrosis. (PMID:19039208)
• addition to granule-stored MBP, even unstimulated eosinophils contained appreciable amounts of MBP within secretory vesicles (PMID:19398958)
• The proMBP is a novel first trimester serum marker for adverse pregnancy outcome. (PMID:19626619)
• novel transcript was alternatively transcribed from intron III of the ENO1 gene and was feasible for MBP-1 production (PMID:20849415)
• Combinations of respiratory syncytial virus and MBP synergistically induced cell death in pulmonary alveolar epithelial cells (A549). (PMID:20977431)
• During pregnancy, the proform of eosinophil major basic protein-angiotensinogen constitutes the major form in late pregnancy. (PMID:23033876)
• Eosinophil major basic protein activates human cord blood mast cells primed with fibroblast membranes by integrin-beta1. (PMID:24112102)
• mRNA levels of eosinophil granule proteins, rather than sputum eosinophil%, may reflect airway hyperresponsiveness and airflow limitation. (PMID:24814827)
• free protein in nasal mucus can be used as a biomarker to diagnose chronic rhinosinusitis (PMID:25266917)
• MBP-1 aggregation is important for innate immunity and immunopathology mediated by eosinophils.MBP-1 toxicity is restrained via crystallization in eosinophil secretory granules. (PMID:25728769)
• Low PRG2 expression is associated with drug resistance in Chronic myeloid leukemia. (PMID:29936783)
• Mechanism of atopic cataract caused by eosinophil granule major basic protein. (PMID:31595373)
• This protein contains a peptide that displays strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, and fungi. (PMID:319906)
• Development and application of novel immunoassays for eosinophil granule major basic proteins to evaluate eosinophilia and myeloproliferative disorders. (PMID:33689807)
• PRG2 and AQPEP are misexpressed in fetal membranes in placenta previa and percretadagger. (PMID:33982062)
• Comparison of pancreatic enzyme abnormalities and protease-activated receptor-2-positive eosinophils in the duodenum of patients with functional dyspepsia-irritable bowel syndrome overlap with functional dyspepsia alone in Asian populations. (PMID:37278449)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Prg2	ENSMUSG00000027073
rattus_norvegicus	Prg2	ENSRNOG00000008394

Paralogs (1): PRG3 (ENSG00000156575)

Protein

Protein identifiers

Bone marrow proteoglycan — P13727 (reviewed: P13727)

Alternative names: Proteoglycan 2

All UniProt accessions (1): P13727

UniProt curated annotations — full annotation on UniProt →

Function. Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.

Subunit / interactions. In pregnancy serum, the proform exists as a disulfide-linked 2:2 heterotetramer with PAPPA, as a disulfide-linked 2:2 heterotetramer with AGT, and as a complex (probably a 2:2:2 heterohexamer) with AGT and C3dg.

Subcellular location. Secreted Cytoplasmic vesicle. Secretory vesicle.

Tissue specificity. Detected in plasma and urine (at protein level). Detected in placenta (at protein level). High levels of the proform in placenta and pregnancy serum; in placenta, localized to X cells of septa and anchoring villi. Lower levels in a variety of other tissues including kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow and colon.

Post-translational modifications. Nitrated.

Miscellaneous. Binds heparin. Does not bind calcium.

Isoforms (2)

UniProt ID	Names	Canonical?
P13727-1	1	yes
P13727-2	2

RefSeq proteins (4): NP_001230174, NP_001289855, NP_001289856, NP_002719* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001304	C-type_lectin-like	Domain
IPR002352	Eosinophil_major_basic	Family
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR033816	EMBP_CTLD	Domain
IPR050111	C-type_lectin/snaclec_domain	Family

Pfam: PF00059

UniProt features (39 total): strand 12, glycosylation site 6, disulfide bond 4, sequence conflict 3, helix 3, chain 2, sequence variant 2, signal peptide 1, splice variant 1, propeptide 1, turn 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
4QXX	X-RAY DIFFRACTION	1.45
1H8U	X-RAY DIFFRACTION	1.8
2BRS	X-RAY DIFFRACTION	2.2
9PPV	ELECTRON CRYSTALLOGRAPHY	3
9PSE	ELECTRON CRYSTALLOGRAPHY	3.18
9PSK	ELECTRON CRYSTALLOGRAPHY	3.18
9DKZ	ELECTRON CRYSTALLOGRAPHY	3.2
7Y5N	ELECTRON MICROSCOPY	3.45
8HGG	ELECTRON MICROSCOPY	3.64

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P13727-F1	76.75	0.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 51, 125–220, 169, 197–212

Glycosylation sites (6): 34, 62, 86, 23, 24, 25

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 496 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, SHEPARD_BMYB_MORPHOLINO_UP, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOCC_SECRETORY_GRANULE, GOCC_CELL_SURFACE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, TGACCTY_ERR1_Q2, MODULE_16, CAGCTG_AP4_Q5, GOBP_CELL_CELL_SIGNALING, MODULE_66, WEI_MYCN_TARGETS_WITH_E_BOX, MODULE_75, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS

GO Biological Process (7): defense response to nematode (GO:0002215), immune response (GO:0006955), negative regulation of macrophage cytokine production (GO:0010936), negative regulation of interleukin-10 production (GO:0032693), positive regulation of interleukin-4 production (GO:0032753), defense response to bacterium (GO:0042742), immune system process (GO:0002376)

GO Molecular Function (4): heparin binding (GO:0008201), extracellular matrix structural constituent conferring compression resistance (GO:0030021), carbohydrate binding (GO:0030246), protein binding (GO:0005515)

GO Cellular Component (6): extracellular region (GO:0005576), transport vesicle (GO:0030133), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), ficolin-1-rich granule lumen (GO:1904813), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
defense response	2
binding	2
response to other organism	1
immune system process	1
response to stimulus	1
negative regulation of cytokine production involved in immune response	1
macrophage cytokine production	1
regulation of macrophage cytokine production	1
negative regulation of cytokine production	1
interleukin-10 production	1
regulation of interleukin-10 production	1
positive regulation of cytokine production	1
interleukin-4 production	1
regulation of interleukin-4 production	1
response to bacterium	1
biological_process	1
glycosaminoglycan binding	1
sulfur compound binding	1
extracellular matrix structural constituent	1
cellular anatomical structure	1
endomembrane system	1
cytoplasmic vesicle	1
external encapsulating structure	1
extracellular vesicle	1
intracellular organelle lumen	1
ficolin-1-rich granule	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

628 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRG2	PAPPA	Q13219	991
PRG2	RNASE2	P10153	944
PRG2	IGFBP4	P22692	819
PRG2	RNASE3	P12724	803
PRG2	CD300A	Q9UGN4	748
PRG2	EPX	P11678	715
PRG2	AGT	P01019	642
PRG2	IL5	P05113	638
PRG2	TNNI3	P19429	548
PRG2	CLC	Q05315	480
PRG2	CRP	P02741	474
PRG2	KITLG	P21583	461
PRG2	CCL11	P50877	454
PRG2	CD34	P28906	422
PRG2	IL5RA	Q01344	418

IntAct

14 interactions, top by confidence:

A	B	Type	Score
PRG2	YPEL5	psi-mi:“MI:0914”(association)	0.640
PRG2	PAPPA	psi-mi:“MI:0915”(physical association)	0.590
PPP1R9A	PRG2	psi-mi:“MI:0915”(physical association)	0.400
PRG2	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
SLC25A11	YES1	psi-mi:“MI:0914”(association)	0.350
SPEM1	PRG2	psi-mi:“MI:0914”(association)	0.350
PRG2	QSOX1	psi-mi:“MI:0914”(association)	0.350
RAB11A	SERPINA3	psi-mi:“MI:0914”(association)	0.350
PRG2	RB1	psi-mi:“MI:0914”(association)	0.350
PRG2	CHD3	psi-mi:“MI:0915”(physical association)	0.000
PRG2	RBM48	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (358): PRG2 (Affinity Capture-MS), PRG2 (Affinity Capture-MS), TUBB3 (Affinity Capture-MS), TUBB8 (Affinity Capture-MS), TUBB1 (Affinity Capture-MS), WDR26 (Affinity Capture-MS), HLA-A (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS), ZNF460 (Affinity Capture-MS), GPRASP2 (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), POTEE (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), ARMC8 (Affinity Capture-MS), PATZ1 (Affinity Capture-MS)

ESM2 similar proteins: A4IFI1, A5A8Y8, D4AB34, E9PY61, O88200, O88201, O95153, P13727, P51693, P55068, P56722, Q03157, Q16849, Q28062, Q3UY90, Q505J3, Q5RKR3, Q5SZI1, Q60673, Q61361, Q63259, Q6GUQ1, Q6PGN1, Q6PRD1, Q6RUU0, Q6UXB4, Q6UXK2, Q766D5, Q76KP1, Q7TNF8, Q80VJ8, Q80XH4, Q8C0R7, Q8CG70, Q8IVL6, Q8K099, Q8K1S7, Q8NCW0, Q8WUT4, Q91V98

Diamond homologs: A6QP79, A7X3Z4, A7X3Z7, P0DQV8, P13727, P26305, P35247, P81018, P82596, Q02988, Q4V885, Q5KU26, Q5M8X6, Q66S03, Q66S37, Q66S50, Q66S54, Q66S65, Q8K4Q8, Q9Y2Y8, P22032, P35709, Q61878, Q63189, Q9JL95, Q61830, Q9UBG0, Q4TU93, O09037, P22897, Q64449, P10758, P20693, Q28062, Q6UXS0

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
EPX	“up-regulates activity”	PRG2	“post translational modification”

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	63
Likely benign	9
Benign	4

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1808639	GRCh37/hg19 18q21.2-23(chr18:53624405-78014123)x1	Pathogenic
816057	GRCh37/hg19 18q22.3-23(chr18:70383594-78014123)x1	Pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1444 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:57387490:G:C	F218L	0.991
11:57387490:G:T	F218L	0.991
11:57387492:A:G	F218L	0.991
11:57387818:A:C	F182L	0.990
11:57387818:A:T	F182L	0.990
11:57387820:A:G	F182L	0.990
11:57387842:C:A	W174C	0.990
11:57387842:C:G	W174C	0.990
11:57387523:C:A	W207C	0.986
11:57387523:C:G	W207C	0.986
11:57389022:A:C	F118L	0.986
11:57389022:A:T	F118L	0.986
11:57389024:A:G	F118L	0.986
11:57388601:C:A	W158C	0.980
11:57388601:C:G	W158C	0.980
11:57387809:C:A	W185C	0.979
11:57387809:C:G	W185C	0.979
11:57387844:A:G	W174R	0.977
11:57387844:A:T	W174R	0.977
11:57388649:A:C	N142K	0.973
11:57388649:A:T	N142K	0.973
11:57387848:A:C	F172L	0.972
11:57387848:A:T	F172L	0.972
11:57387850:A:G	F172L	0.972
11:57388603:A:G	W158R	0.967
11:57388603:A:T	W158R	0.967
11:57387525:A:G	W207R	0.959
11:57387525:A:T	W207R	0.959
11:57387826:A:G	W180R	0.959
11:57387826:A:T	W180R	0.959

dbSNP variants (sampled 300 via entrez): RS1000878535 (11:57387723 T>C), RS1002892513 (11:57390110 C>T), RS1003107304 (11:57391750 C>G), RS1003174975 (11:57391273 T>C), RS1003634765 (11:57391586 G>A,T), RS1004495947 (11:57390615 G>C), RS1005324558 (11:57386928 T>G), RS1005466159 (11:57391142 T>C), RS1005664568 (11:57388149 T>C), RS1006001504 (11:57389436 G>A,C,T), RS1006056845 (11:57391706 G>A), RS1006106005 (11:57391438 C>T), RS1006940417 (11:57388682 G>A,C), RS1007512439 (11:57388919 A>C), RS1009019167 (11:57392015 C>T)

Disease associations

OMIM: gene MIM:605601 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001438_11	Crohn’s disease	8.000000e-09
GCST001578_1	Age-related macular degeneration (geographic atrophy)	4.000000e-07
GCST002701_38	Verbal declarative memory	2.000000e-06
GCST002726_62	Glucose homeostasis traits	8.000000e-06
GCST003448_4	Erythrocyte cadmium concentration in never smokers	3.000000e-06
GCST004267_8	Blood osmolality (transformed sodium)	3.000000e-07
GCST005352_23	Paclitaxel disposition in epithelial ovarian cancer	3.000000e-06
GCST006427_38	Depression in smokers	6.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:1001492	atrophic macular degeneration
EFO:0004874	memory performance
EFO:0006805	word list delayed recall measurement
EFO:0006830	insulin metabolic clearance rate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzene	affects expression	2
Smoke	increases expression	2
bisphenol F	affects cotreatment, decreases methylation	1
2,4,6-tribromophenol	increases expression	1
bisphenol A	decreases expression	1
decabromobiphenyl ether	increases expression	1
kojic acid	decreases expression	1
sulforaphane	decreases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	increases expression	1
ochratoxin A	increases expression	1
tebuconazole	decreases expression	1
CGP 52608	affects binding, increases reaction	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	increases expression	1
Aripiprazole	affects cotreatment, increases expression	1
Decitabine	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Arbutin	decreases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	decreases expression	1
Diethylnitrosamine	increases expression	1
Ozone	affects cotreatment, increases expression	1
Valproic Acid	increases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
beta-Naphthoflavone	decreases expression	1
Copper Sulfate	increases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1LG	Abcam Jurkat PRG2 KO	Cancer cell line	Male
CVCL_D1Q1	Abcam K-562 PRG2 KO	Cancer cell line	Female
CVCL_D2LM	Abcam Raji PRG2 KO	Cancer cell line	Male
CVCL_E0WL	Ubigene Jurkat, Clone E6-1 PRG2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.